PressJuly 3, 2023 FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
PressJune 30, 2023 Filament Health Enters Exclusive Licensing Agreement With Neolumina Bioscience Inc.
PressJune 29, 2023 Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
PressJune 29, 2023 Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
PressJune 27, 2023 PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
PressJune 27, 2023 Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
PressJune 27, 2023 Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
PressJune 23, 2023 Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
PressJune 22, 2023 BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
PressJune 20, 2023 PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
PressJune 20, 2023 Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001
